QR Genetics combines proprietary datasets, computational biology, and GenAI analytics to uncover the molecular mechanisms underlying rare genetic diseases and identify potential therapeutic targets. The company seeks to match these targets with clinically validated, FDA-approved drugs, supporting a faster and lower-risk drug-repurposing pathway, while building a library of validated targets that can be applied to genetically and mechanistically related common diseases. QR Genetics partners with pharmaceutical companies to advance target validation and drug-development programs toward clinical trials.
